Please assess the completion status of the following clinical trial:

Trial Title: Targeted Therapy of Bronchiolitis Obliterans Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of BOS after HCT within the 6 months before study enrollment; for this study, BOS is defined as:~  * Forced expiratory volume in 1 second (FEV1) \< 75% of the predicted normal and FEV1 to slow or inspiratory vital capacity ratio (FEV1/SVC or FEV1/IVC) =\< 0.7, both measured before and after administration of bronchodilator OR~ * Pathologic diagnosis of BOS demonstrated by lung biopsy~* The baseline absolute FEV1 must be \>= 10% lower than the pre-transplant absolute FEV1 as defined by the pre-transplant FEV1 minus the baseline FEV1, both measured before administration of a bronchodilator~* Participant (or parent/guardian) has the ability to understand and willingness to sign a written consent document~Exclusion Criteria:~* Recurrent or progressive malignancy requiring anticancer treatment~* Known history of allergy to or intolerance of montelukast, zafirlukast, azithromycin, erythromycin, or clarithromycin~* Pregnancy or nursing; all females of childbearing potential must have a negative serum or urine pregnancy test \< 7 days before study drug administration~* Transaminases \> 5 X upper limit of normal (ULN)~* Total bilirubin \> 3 X ULN~* Chronic treatment with any inhaled steroid for \> 1 month in the past three months~* Treatment with montelukast or zafirlukast for \> 1 month during the past three months~* Treatment with prednisone at \> 1.2 mg/kg/day (or equivalent steroid)~* Treatment with rifampin or phenobarbital, aspirin at doses \> 325 mg/day, or ibuprofen at doses \> 1200 mg/day~* Treatment with any Food and Drug Administration (FDA) non approved study medication within the past 4 weeks; off-label treatment with an FDA-approved medication is allowed~* Chronic oxygen therapy~* Evidence of any viral, bacterial or fungal infection involving the lung and not responding to appropriate treatment~* Clinical asthma (variable and recurring symptoms of airflow obstruction and bronchial hyper-responsiveness)~* Any condition that, in the opinion of the enrolling investigator, would interfere with the subject's ability to comply with the study requirements~* Uncontrolled substance abuse or psychiatric disorder~* Inability to perform pulmonary function tests (PFT) reliably, as determined by the enrolling investigator or PFT lab~* Life expectancy \< 6 months at the time of enrollment as judged by the enrolling investigator~* Baseline post-bronchodilator FEV1 \< 20% of predicted normal before or after albuterol

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (BOS therapy) (Type: EXPERIMENTAL): Patients receive fluticasone propionate inhaled PO BID, azithromycin PO 3 days a week, and montelukast sodium PO QD. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).